| MeSH term | MeSH ID | Detail |
|---|---|---|
| Carcinoma | D002277 | 18 associated lipids |
| Carcinoma, Non-Small-Cell Lung | D002289 | 72 associated lipids |
| Carcinoma, Papillary | D002291 | 3 associated lipids |
| Carcinosarcoma | D002296 | 7 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Celiac Disease | D002446 | 16 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Cherubism | D002636 | 1 associated lipids |
| Chondroblastoma | D002804 | 1 associated lipids |
| Chondrocalcinosis | D002805 | 1 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Tanaka S et al. | Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. | 2005 | Immunol. Rev. | pmid:16313339 |
| Horowitz MC et al. | B cells and osteoblast and osteoclast development. | 2005 | Immunol. Rev. | pmid:16313346 |
| Clowes JA et al. | The role of the immune system in the pathophysiology of osteoporosis. | 2005 | Immunol. Rev. | pmid:16313351 |
| Walsh NC et al. | Rheumatic diseases: the effects of inflammation on bone. | 2005 | Immunol. Rev. | pmid:16313352 |
| Boyce BF et al. | Osteoprotegerin, the bone protector, is a surprising target for beta-catenin signaling. | 2005 | Cell Metab. | pmid:16330319 |
| Wang Q et al. | [The molecule mechanism of soybean isoflavaones antagonizing bone loss induced by postmenopausal osteoporosis]. | 2005 | Zhong Yao Cai | pmid:16479929 |
| Guang-Da X et al. | Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients. | 2005 | J. Endocrinol. Invest. | pmid:16483173 |
| Liu JM et al. | Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. | 2005 | Calcif. Tissue Int. | pmid:15455183 |
| Wang YD et al. | [Predominant effect of bushen ningxin decoction on postmenopausal osteoporosis in mice]. | 2005 | Zhongguo Zhong Xi Yi Jie He Za Zhi | pmid:16355616 |
| Xiao HL et al. | [Expression and activity determination of TNFR domain of osteoprotegerin in E.coli and corresponding antibody preparation]. | 2005 | Yi Chuan | pmid:16257908 |
| Liu W et al. | Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. | 2005 | J. Biol. Chem. | pmid:16260781 |
| Hormdee D et al. | Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. | 2005 | Clin. Exp. Immunol. | pmid:16297161 |
| Geusens P and Reid D | Newer drug treatments: their effects on fracture prevention. | 2005 | Best Pract Res Clin Rheumatol | pmid:16301192 |
| Hamdy NA | Osteoprotegerin as a potential therapy for osteoporosis. | 2005 | Curr Osteoporos Rep | pmid:16303111 |
| Wiercinska-Drapalo A et al. | Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. | 2005 | Prostaglandins Other Lipid Mediat. | pmid:16303613 |
| Tarquini R et al. | Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. | 2005 | Biomed. Pharmacother. | pmid:16275499 |
| Cozzani M et al. | Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption. | 2005 | Prog Orthod | pmid:16276433 |
| Gaudio A et al. | Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role? | 2005 | J. Endocrinol. Invest. | pmid:16277162 |
| Burton DW et al. | Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. | 2005 | Prostate | pmid:15389781 |
| Zahanich I et al. | Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells. | 2005 | J. Bone Miner. Res. | pmid:16059635 |
| Cao JJ et al. | Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. | 2005 | J. Bone Miner. Res. | pmid:16059637 |
| Terpos E et al. | The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. | 2005 | Leukemia | pmid:16079895 |
| Stenman UH et al. | Prognostic value of serum markers for prostate cancer. | 2005 | Scand J Urol Nephrol Suppl | pmid:16019759 |
| Guang-da X et al. | Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. | 2005 | J. Clin. Endocrinol. Metab. | pmid:16046585 |
| Kazama JJ et al. | Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. | 2005 | Clin. Nephrol. | pmid:16047647 |
| Ziegler S et al. | Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. | 2005 | Atherosclerosis | pmid:16115489 |
| Gonnelli S et al. | Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. | 2005 | J. Endocrinol. Invest. | pmid:16117195 |
| Zhou Z et al. | Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. | 2005 | Cancer | pmid:16121404 |
| Ashcroft AJ and Carding SR | RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation. | 2005 | Gut | pmid:16099805 |
| Pantouli E et al. | Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. | 2005 | Biochem. Biophys. Res. Commun. | pmid:15721297 |
| Korcok J et al. | P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. | 2005 | J. Biol. Chem. | pmid:15722352 |
| Kiviranta R et al. | Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. | 2005 | Bone | pmid:15664014 |
| Avbersek-Luznik I et al. | Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? | 2005 | Nephrol. Dial. Transplant. | pmid:15665031 |
| Bhatia P et al. | Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. | 2005 | Clin. Cancer Res. | pmid:15671541 |
| Schneider HG and Sentry J | Multiple myeloma. | 2005 | N. Engl. J. Med. | pmid:15736296 |
| Bock O et al. | Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. | 2005 | J. Pathol. | pmid:15726648 |
| Skládal P et al. | Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. | 2005 | Biosens Bioelectron | pmid:15741072 |
| Mosheimer BA et al. | Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. | 2005 | J. Clin. Endocrinol. Metab. | pmid:15728209 |
| Kanno T et al. | Platelet-rich plasma enhances human osteoblast-like cell proliferation and differentiation. | 2005 | J. Oral Maxillofac. Surg. | pmid:15742288 |
| Han KO et al. | The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. | 2005 | Clin. Endocrinol. (Oxf) | pmid:15730418 |
| Nagasaki T et al. | Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. | 2005 | Eur. J. Endocrinol. | pmid:15757850 |
| Simmons CA et al. | Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. | 2005 | Circ. Res. | pmid:15761200 |
| Gallant MA et al. | Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. | 2005 | J. Bone Miner. Res. | pmid:15765187 |
| Zannettino AC et al. | Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. | 2005 | J. Cell. Physiol. | pmid:15799029 |
| Tada T et al. | Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. | 2005 | Int. J. Cancer | pmid:15800904 |
| Skoumal M et al. | Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. | 2005 | Rheumatol. Int. | pmid:15889303 |
| Inoue H et al. | Prostate cancer mediates osteoclastogenesis through two different pathways. | 2005 | Cancer Lett. | pmid:15890244 |
| Lynch CC et al. | MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. | 2005 | Cancer Cell | pmid:15894268 |
| Chang K et al. | Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating factor. | 2005 | J. Orthop. Res. | pmid:15913941 |
| Depil S et al. | Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. | 2005 | Br. J. Haematol. | pmid:15916694 |
| Mesquita M et al. | Bone cytokines and renal osteodystrophy in peritoneal dialysis patients. | 2005 | Adv Perit Dial | pmid:16686314 |
| Glass DA et al. | Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. | 2005 | Dev. Cell | pmid:15866165 |
| Grzegorzewska AE and Mlot M | Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients. | 2005 | Adv Perit Dial | pmid:16686316 |
| Valenta A et al. | Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. | 2005 | Bone | pmid:15869920 |
| Chan MH et al. | Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. | 2005 | Pathology | pmid:15875734 |
| Seminari E et al. | Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. | 2005 | HIV Med. | pmid:15876279 |
| Schett G et al. | Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. | 2005 | Arthritis Rheum. | pmid:15880601 |
| Moe SM et al. | Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). | 2005 | Kidney Int. | pmid:15882271 |
| Ueland T et al. | Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. | 2005 | Circulation | pmid:15883214 |
| Sabokbar A et al. | Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. | 2005 | J. Orthop. Res. | pmid:15885469 |
| Mazziotti G et al. | Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. | 2005 | J. Bone Miner. Res. | pmid:15746993 |
| Corey E et al. | Osteoprotegerin in prostate cancer bone metastasis. | 2005 | Cancer Res. | pmid:15753366 |
| Moschen AR et al. | The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. | 2005 | Gut | pmid:15753532 |
| Mandelin J et al. | Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. | 2005 | J. Biomed. Mater. Res. Part B Appl. Biomater. | pmid:15768436 |
| Crisafulli A et al. | Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. | 2005 | Menopause | pmid:15772566 |
| Mizuno N et al. | Characterization of epithelial cells derived from periodontal ligament by gene expression patterns of bone-related and enamel proteins. | 2005 | Cell Biol. Int. | pmid:15774307 |
| Indridason OS et al. | Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. | 2005 | Osteoporos Int | pmid:15776220 |
| Ling LJ et al. | Areca nut extracts modulated expression of alkaline phosphatase and receptor activator of nuclear factor kappaB ligand in osteoblasts. | 2005 | J. Clin. Periodontol. | pmid:15811051 |
| Maïmoun L et al. | Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. | 2005 | Calcif. Tissue Int. | pmid:15812577 |
| Ulrich-Vinther M and Andreassen TT | Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. | 2005 | Calcif. Tissue Int. | pmid:15812581 |
| Ishizuka K et al. | Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. | 2005 | Neurosci. Lett. | pmid:15814197 |
| Ulrich-Vinther M et al. | Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. | 2005 | Bone | pmid:16169783 |
| Cui N et al. | Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. | 2005 | Clin. Cancer Res. | pmid:15814653 |
| Lossdörfer S et al. | PTH(1-34) affects osteoprotegerin production in human PDL cells in vitro. | 2005 | J. Dent. Res. | pmid:15972592 |
| Hjertner Ø et al. | Identification of new targets for therapy of osteolytic bone disease in multiple myeloma. | 2005 | Curr Drug Targets | pmid:16178802 |
| Arko B et al. | Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. | 2005 | Maturitas | pmid:15978970 |
| Otsuka T et al. | Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures. | 2005 | J Dent | pmid:16199283 |
| Neumann E et al. | The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. | 2005 | Arthritis Rheum. | pmid:16200575 |
| Koh JM et al. | Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. | 2005 | J. Endocrinol. | pmid:15930166 |
| Liu D et al. | Chronology and regulation of gene expression of RANKL in the rat dental follicle. | 2005 | Eur. J. Oral Sci. | pmid:16202028 |
| Bhattacharya A et al. | Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by N-3 fatty acids. | 2005 | J Am Coll Nutr | pmid:15930486 |
| Xie F et al. | Increase in bone mass and bone strength by Sambucus williamsii HANCE in ovariectomized rats. | 2005 | Biol. Pharm. Bull. | pmid:16204939 |
| Juarranz Y et al. | Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. | 2005 | Arthritis Res. Ther. | pmid:16207319 |
| Kerschan-Schindl K et al. | Serum levels of cathepsin K decrease with age in both women and men. | 2005 | Exp. Gerontol. | pmid:15935595 |
| Görtz B et al. | Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. | 2005 | Arthritis Res. Ther. | pmid:16207331 |
| Ugur-Altun B et al. | The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. | 2005 | Diabetes Res. Clin. Pract. | pmid:15936463 |
| Kostenuik PJ | Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. | 2005 | Curr Opin Pharmacol | pmid:16188502 |
| Whang PG et al. | The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. | 2005 | J. Orthop. Res. | pmid:16005175 |
| Sakakura Y et al. | Immunolocalization of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) in Meckel's cartilage compared with developing endochondral bones in mice. | 2005 | J. Anat. | pmid:16191162 |
| Bashir A et al. | Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. | 2005 | Steroids | pmid:16005483 |
| Meng XM et al. | [Expression of receptor activator of NF-kappa B ligand and osteoprotegerin protein in the giant cell lesions of jaw]. | 2005 | Zhonghua Kou Qiang Yi Xue Za Zhi | pmid:16191370 |
| Khosla S | Magic bullets to kill nasty osteoclasts. | 2005 | Endocrinology | pmid:16009971 |
| Tabuchi M et al. | Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. | 2005 | Calcif. Tissue Int. | pmid:16193235 |
| Feng X | RANKing intracellular signaling in osteoclasts. | 2005 | IUBMB Life | pmid:16012047 |
| Kusumi A et al. | Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain. | 2005 | J. Bone Miner. Metab. | pmid:16133687 |
| Moran CS et al. | Association of osteoprotegerin with human abdominal aortic aneurysm progression. | 2005 | Circulation | pmid:15939823 |
| Sakai A et al. | Osteoclast development in immobilized bone is suppressed by parathyroidectomy in mice. | 2005 | J. Bone Miner. Metab. | pmid:15616888 |
| Sasaki N et al. | Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). | 2005 | J. Bone Miner. Metab. | pmid:15616893 |
| Masui T et al. | Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. | 2005 | Biomaterials | pmid:15576143 |
| Manganelli P et al. | OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? | 2005 | Clin. Rheumatol. | pmid:15583970 |